Loxo Oncology (Loxo Oncology) Receivables Turnover : 0.00 (As of Sep. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Loxo Oncology Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Loxo Oncology's Revenue for the three months ended in Sep. 2018 was $42.5 Mil. Loxo Oncology's average Accounts Receivable for the three months ended in Sep. 2018 was $0.0 Mil.

Loxo Oncology Receivables Turnover Historical Data

The historical data trend for Loxo Oncology's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Loxo Oncology Receivables Turnover Chart

Loxo Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Receivables Turnover

Loxo Oncology Quarterly Data
	Sep13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Loxo Oncology's Receivables Turnover

For the Biotechnology subindustry, Loxo Oncology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Loxo Oncology's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Loxo Oncology's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Loxo Oncology's Receivables Turnover falls into.

Loxo Oncology Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Loxo Oncology's Receivables Turnover for the fiscal year that ended in Dec. 2017 is calculated as

	Receivables Turnover (A: Dec. 2017 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2017 )	/ (	(Accounts Receivable (A: Dec. 2016 )	+	Accounts Receivable (A: Dec. 2017 ))	/	count )
=	21.3	/ (	(0	+	0)	/	1 )
=	21.3	/	0
=	N/A

Loxo Oncology's Receivables Turnover for the quarter that ended in Sep. 2018 is calculated as

	Receivables Turnover (Q: Sep. 2018 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Sep. 2018 )	/ (	(Accounts Receivable (Q: Jun. 2018 )	+	Accounts Receivable (Q: Sep. 2018 ))	/	count )
=	42.47	/ (	(0	+	0)	/	1 )
=	42.47	/	0
=	N/A

Loxo Oncology (NAS:LOXO) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Loxo Oncology Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Loxo Oncology's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Loxo Oncology (Loxo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Loxo Oncology Inc (NAS:LOXO) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.loxooncology.com

Loxo Oncology Inc develops medicines for patients with genetically defined cancers. Its approach is based on the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building inhibitors against single targets in the cancer cell. Its pipeline of products includes Larotrectinib, Loxo etc.

Executives

Jennifer Burstein	officer: Senior VP of Finance	C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Keith T. Flaherty	director	55 FRUIT STREET, YAWKEY 9E, BOSTON MA 02114
Lori Anne Kunkel	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Joshua H. Bilenker	director, officer: President & CEO	C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Steve Elms	director, 10 percent owner	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alan Fuhrman	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Dennis J Purcell	10 percent owner	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Aisling Capital Iii Lp	10 percent owner	888 Seventh Avenue, 30th Fl, New York NY 10106
Aisling Capital Partners Iii Lp	10 percent owner	AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iii Llc	10 percent owner	AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp V Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022